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The standard of care for glioblastoma (GB) is surgery followed by concurrent radiation therapy (RT) and temozolomide
(TMZ) and then adjuvant TMZ. This regime is associated with increased survival but also increased occurrence of
equivocal imaging findings, e.g., tumor progression (TP) versus treatment effect (TE), which is also referred to as
pseudoprogression (PsP). Equivocal findings make decisions regarding further treatment difficult and often delayed.
Because none of the current imaging assays have proven sensitive and specific for differentiation of TP versus TE/PsP,
we investigated whether blood-derived microvesicles (MVs) would be a relevant assay.METHODS: 2.8 ml of citrated
blood was collected from patients with GB at the time of their RT simulation, at the end of chemoradiation therapy
(CRT), and multiple times following treatment. MVs were collected following multiple centrifugations (300g, 2500g,
and 15,000g). The pellet from the final spinwas analyzed using flow cytometry. A diameter of approximately 300 nmor
greater and Pacific Blue–labeled Annexin V positivity were used to identify the MVs reported herein. RESULTS: We
analyzed 19 blood samples from 11 patients with GB. MV counts in the patients with stable disease or TE/PsP were
significantly lower than patients who developed TP (P = .014). CONCLUSION: These preliminary data suggest that
blood analysis for MVs from GB patients receiving CRT may be useful to distinguish TE/PsP from TP. MVs may add
clarity to standard imaging for decision making in patients with equivocal imaging findings.
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© 2014 Neoplasia Press, Inc. Published by Elsevier Inc. This is an open access articleThe current standard of care for glioblastoma (GB) includes the use of
temozolomide (TMZ)–based chemoradiation therapy (CRT) following
debulking surgery [1,2]. The TMZ-based CRT regime has increased
survival [1,2] but has also increased the frequency of false positive post-
treatment magnetic resonance imaging (MRI) assessments of tumor
progression (TP) [3]. In roughly 30% of patients, TP cannot reliably be
distinguished on imaging from pseudoprogression (PsP) [3], a type of
treatment effect (TE).1 This has resulted in difficult and/or delayeddecision making regarding further treatment [3]. New neuroimaging
techniques are not yet capable of accurately distinguishing TE/PsP fromunder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Table 1. Patient Demographics
Sex Male = 6
Female = 5
Age Average = 61 (range, 45-75)
Surgery
Location Temporal = 3/11
Parietal = 3/11
Frontal = 5/11
Extent of resection NTR = 2/11
GTR = 2/11
STR = 6/11
Biopsy only: 1
Progression between surgery and simulation 2 of 10 (biopsied patient not included)
Pathologic features
Tumor type (primary) 11 of 11 GB
Ki67 Average = 29% (8-70%)
Absence of pseudopalisading necrosis 2 of 11
Absence of microvascular proliferation 2 of 11
EGFR IHC Average = 2.71 *
EGFR vIII (RT-PCR) 6 of 11 positive
MGMT methylation 2 of 9 unmethylated
IDH1 IHC 11 of 11 negative
p53 IHC † Average = 2.18
Recurrent tumor type based on surgery 3; GBM with necrosis
Outcomes
Clinical status at the time of analysis 2 of 11—DOD
6 of 11—alive with progression
3 of 11—alive without progression
NTR: near total resection; GTR: gross total resection; STR: subtotal resection; GB: glioblastoma;
DOD: dead of disease.
* EGFR: scale is 0 (no membranous staining), 1 (weak staining), 2 (moderate), and 3 (strong).
† p53: scale is 0 (no staining), 1 (subset positive cells), 2 (moderate), and 3 (strong, majority of tumor cells).
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additional therapies for patientswithTE/PsPmay improve patient outcome.
It will also decrease the number of patients needed for clinical trials [4].
Sparse molecular markers that are shed from tumors into the
circulation may be assessed from a “liquid biopsy.” Extracellular vesicles
(ECVs), “naked” DNA, and circulating tumor cells are examples of
biomarkers that may be isolated from a blood sample. ECVs are
membrane-derived, organelle-like structures. They are referred to by
many names, including exosomes, microparticles, and microvesicles
(MVs). We use the term MVs to refer to vesicles N300 nm in diameter
versus exosomes that are b300 nm.2 The larger MVs can be interrogated
using flow cytometry (FCM) with fluorescent conjugated surface
markers. Both normal (i.e., red blood cells, B and T cells, platelets, and
macrophages) and cancer cells secrete a heterogeneous mixture of ECV
into the tumor interstitial spaces and the circulation [5]. Both exosomes
andMVs have been shown to act as signaling complexes in disease and are
generally associated with a poor prognosis [6]. We hypothesized that the
number of Annexin V–positive3 circulatingMVs (based on FCM) could
be used as a biomarker for the differentiation of TP from TE/PsP in GB.
Methods
Patients and Volunteers
Patients and volunteers signed University of Pennsylvania
Institutional Review Board–approved informed consent for this
study. All patients had a diagnosis of GB and surgery was their only
treatment before entry into this protocol. Samples for MV analysis
were obtained from patients as long as they were receiving standard2 There are many definitions in the literature regarding the size range of exosomes versus MVs. Herein, we
selected the cutoff at 300 nm because this is the smallest particle size that can be delineated by flow cytometry.
3 Annexin V is a marker of phosphotidylserine (PS), which is found on the outside surface of MVs.therapy (additional surgery, radiation, TMZ, and Avastin); MV data
were not included in this study once a patient began a therapeutic
vaccine-based experimental study.
Clinical, Radiographic, and Histopathologic Assessments
For this study, a central review by one pathologist (M.M.-L.) was
performed (Table 1). All patients were diagnosed with GB at their first
surgery, and for all patients with TP who received a second surgery, the
diagnosis was GB with treatment-related necrosis and other treatment-
related changes. MRI images were made following surgery, at the time of
simulation for CRT, and at 1, 3, 6, 12, and 24 months after CRT. All of
theseMRI studies were centrally reviewed (R.L.W.), recording the sum of
products of greatest transverse dimensions for enhancing lesions and
products of greatest transverse dimensions of flair regions, as described by
the Response Assessment in Neuro-Oncology (RANO) criteria [7].
Therapy
Maximum safe surgical resection was performed. Approximately 40 to
45 days later, patients underwent computerized tomography/MRI-based
treatment planning. The initial volume of the cavity plus the MRI-
determined enhancing tumor and flair abnormality volumes were
expanded by 1.5 cm and treated at 200 cGy per fraction to 4600 cGy.
The fields were then decreased in size to include the cavity and enhancing
tissue and continued at 200 cGy per fraction to 6000 cGy for a total of 30
fractions. All patients received concurrent daily TMZ at 75 mg/M2 and
began adjuvant TMZ approximately 1 month after radiation. As patients
experienced TP, they were assigned to a modified or additional treatment
or a clinical trial considered optimal by their physician.
Blood Collection
Following completion of Institutional ReviewBoard–approvedwritten
informed consent, peripheral blood was obtained from patients with GB
and healthy volunteers. The exclusion criteria for healthy volunteers were
that they were b18 years old and had a previous history and/or current
malignancy. For both volunteers and patients with GB, 2.8 ml of blood
was collected into a plastic sodium citrate vacutainer tube (BD Scientific,
Franklin Lakes, NJ; 363083). Several volunteers agreed to a second
sample at a later date, whereas the patients with GB had longitudinal
sampling as mentioned above. Because this was a preliminary study,
blood draws for MVs were not performed at every imaging session
(described above). Thus, we compared MRI images with the nearest
temporal assessment of circulating MVs.
Blood tubes weremaintained in a vertical position at room temperature
until addition of a fixative (Caltag; Fix and PermMedium A, Invitrogen,
Carlsbad, CA), approximately 1 hour after blood collection.
Timing of Samples
Samples were collected from patients with GB within 2 weeks before
CRT simulation, at the end of CRT, and at 1, 3, 6, 12, and 24 months
after CRT. Patients were taken off the study if they or their treating
physician requested this, or they experienced extraordinary medical
circumstances. Analysis of blood samples taken after a patient started an
experimental vaccine therapy was not included in this analysis.
Blood Processing
Blood (0.9 ml) was added to 0.1 ml of filtered Caltag A and
allowed to stand at room temperature for approximately 60 minutes.
Red and white cells were removed by a 20-minute spin (20°C) at 300g
using a swinging bucket centrifuge with brake set at 0 (Allegra X-22
R; Beckman Coulter, Pasadina, CA). The supernatant (0.4 ml;
Figure 1. This figure shows a representative image of MV from
human blood made with a cryo-transmission electron microscope.
In the image, the outer ring that contains the main group of MV is
part of the grid holding the sample (arrowhead). Vesicles of various
sizes and shapes are identified, some with diameters less than 300
nm (scale bar, 200 nm). The contents of several MVs can be seen
as densities or shapes inside the MV. Released contents and/or
plasma proteins are also seen (arrow). The majority of the vesicles
that were seen in approximately 50 fields were intact, similar to that
seen in this image.
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200 μl) and mixed thoroughly with 0.6 ml of minimal buffer citrate
(standard NaCl and KCl, with 10 mM Hepes and 11 mM sodium
citrate). This was further spun at 2500g for 20 minutes (same
centrifuge) to produce a platelet pellet and platelet-free supernatant;
0.8 ml of the latter was then removed, 200 μl saved, and the
remaining 600 μl spun at 15,000g for 30 minutes at 20°C (swinging
bucket, Microfuge 22R; Beckman Coulter). Four hundred microliters
of supernatant was removed and half of this was saved (high-speed
supernatant), leaving 200 μl above the high-speed pellet (HSP). All
samples thus consisted of 200 μl of sample, and each of these was
diluted with an equal volume of filtered minimal buffer and 10%
DMSO and frozen (5 minutes at −27°C, plunged to dry ice or at a
lower temperature, and stored at −75°C). The vast majority of MVs
was contained in the HSP, and this is the basis of the data presented.
Flow Cytometry
Samples were thawed at 37°C (less than 2 minutes) in a Multi-Blok
heater (Barnstead/Lab-Line Multi-Blok® Heaters, Thermo Scientific,
Ashville,NC) and gently vortexed. To detectMVs,minimal buffer with 3
mm Ca2+ was supplemented with Pacific Blue (PB)–labeled Annexin V
and PE-labeled anti-epidermal growth factor receptor (EGFR)4 [8,9].
This solution was filtered with a 0.2-μmnon–protein-binding filter5 and
was then supplemented with 3-μmbeads (Spherotech BCP-30) to a final
concentration of 50,000/ml (“analysis solution”). For each sample, MV-
containing HSP was added to 200 μl of analysis solution in a FCM tube
held at room temperature for 30 minutes and then stored on ice until
FCM analysis (less than 2.5 hours). A FACS-Canto, three-laser
instrument (violet, blue, and red) was set so that the 3-μm beads were
situated at about 105 on both forward scatter (FSC) and side scatter log
scales. Under these conditions, 1-μm beads were easily observed where
expected, but 0.3-μmbeads were only partially resolved depending on the
daily “mood” of the cytometer. The fluorescent scales were set so that
background fluorescence from the 3-μmbeads (no fluorescence stain) was
at ~2000. Each sample was run at medium speed until 4000 beads were
counted (0.08 ml at ~2 minutes), and the results were analyzed using
FlowJo software.
Electron Microscopy
C-flat holey carbon transmission electron microscope grids (Proto-
chips, Raleigh, NC) were glow discharged for 20 seconds at 25 mA to
create a hydrophilic surface for the 3 μl of blood plasma. A thin film was
formed by blotting the grid with filter paper. Vitreous ice was formed by
rapid plunging into liquid ethane cooled to −180°C by liquid nitrogen.
Grids were cryogenically observed at −178°C in an FEI (Hillsboro, OR)
Tecnai-12 microscope, which was operated at 80 keV at magnification as
indicated in the figure legends. Images were recorded on a Gatan
(Warrendale, PA) US 1000 20482 CCD camera.
Statistics
Analysis of differences between MV values occurring in temporal
association with the diagnosis of TP versus TE/PsP and in volunteers
was calculated using the Student's t test and expressed in a “box and
whisker” plot.4 EGFR vIII was not measured in the MVs collected but was determined on the surgical specimen by
reverse transcription–polymerase chain reaction (RT-PCR).
5 It should be noted that no MV-containing solution was filtered.Results
Seven volunteers (threemales and four females, ages 30 to 68) and 15GB
patients were accrued to the study. Four of the seven volunteers allowed a
second blood draw at a later time. Four patients with GB withdrew from
the study before the completion of CRT and were eliminated from
further analysis. Thus, data are reported on 11 patients and 7 volunteers.
Six patients were male and five were female; all were Caucasian. The
average age at diagnosis of GBwas 61 (range, 45-75; Table 1). All patients
had a centrally confirmed surgical diagnosis of GB from their initial
surgery; three patients who underwent second surgery had GB with
varying degrees of necrosis (15%, 20%, and 60%). Review of MRI
studies following surgery (within 24 hours) demonstrated that six patients
had subtotal resection, two had gross total resection, and two had near
total resection. One patient had a stereotactic biopsy due the extent
and location of the tumor. Immunohistochemical (IHC) molecular
markers indicated that none of the tumors were isocitrate dehydrogenase
mutant positive, 2 of 9 were methylguanine-DNA methyltransferase
(MGMT) unmethylated,6 and 6 of 11 had EGFR vIII mutations (based
on real-time polymerase chain reaction). The p53 status, based on IHC
(range, 1-3 with 3 being strongly positive), averaged 2.18, and the EGFR
averaged 2.7 on the same scale. The average Ki67 count was 29% (range,
8-70%; Table 1).
At the time of simulation, all patients showed nontarget
enhancement (nonmeasurable or less than 1 ml), five had target
enhancement (measurable enhancement or 1 ml or greater), five had
no target enhancement, and one could not be assessed due to
excessive motion. RANO values could be determined in 11 of 21
MRI images. After CRT, the first imaging study (baseline) showed 86 Two patients did not have MGMT methylation status evaluated.
Figure 2. (Left) An FCM example of differently sized polystyrene beads (0.3, 1, and 3 μm diameter) as a size control for sample studies.
(Right) An example of the FCM output from a GB patient’s blood prepared for MV analysis. The graph shows an area of interest as defined
by PB-conjugated Annexin V plotted against FSC. A clearly defined separate population can be identified as MVs. Note that the FSC and
side scatter thresholds were set to 250, so nothing less than that value can be seen.
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compared to the simulation study. Five of the eight with target
enhancement were equivocal for TE/PsP versus TP with an increase
in enhancing volume ranging from 17% to 164% compared to
simulation volume; all of these patients had shown mild or
convincing progression on the simulation study. Two of these
patients required re-resection after baseline MRI. On follow-up after
the end of CRT, one patient showed equivocal changes over time,
eventually developing slowly evolving target enhancement. Two
patients with suspect baseline MRI showed continuing progression
on follow-up, and another developed progressive enhancement by the
first post-baseline MRI and thereafter. The other patient with
concern for progression on baseline improved. The MRI findings in
the remaining patients were relatively stable or improved over
additional studies.
The MV count in seven normal volunteers ranged from 193 to
4300 raw MV counts.7 One of the volunteers had an MV count that
was four to five times higher than the other values, and therefore, we
used the median (vs mean) value of 965 as a working value for the
cutoff for “normal” Annexin V–positive MV. Four of the volunteers
had two MV analyses over 2 to 19 months. The differences between
the paired MV values ranged from 4.2% to 51.0%.
Figure 1A shows the cryo-transmission electron microscopy images
of vesicles from a volunteer’s blood sample. Vesicles of various sizes
and shapes are identified inside of the supporting grid (arrowhead);
some exosomes with diameters less than 300 nm are present.
The background material (arrow) is plasma protein or spilled MV
contents. The great majority of the vesicles seen in approximately
50 fields were intact, supporting that the serial centrifugation and
freeze/thaw processes did not damage them.
Figure 2 shows the FCM control study of 0.3-, 1.0-, and 3.0-μm
polystyrene beads. The largest beads are well delineated and are used to
calibrate the FCM machine so that the data can be compared over7 To convert raw MV counts to MV per milliliter of plasma, the raw MV count should be multiplied by
the dilution factor.time. An example of FCM of MV from a patient with GB is shown in
Figure 2B. Events of interest are based on Annexin V-postivie binding.
Annexin V binds to PS, which is conjugated to the fluorochrome PB.
In the figure, these events are plotted against FSC. The Annexin V PB
positive, low FSC population represents rawMV counts (see region of
interest). These values, multiplied by the dilution factor, are equal to
the number of MV per milliliter of plasma. In addition to Annexin V,
MV samples were stained for EGFR. All MV samples from patients
with GB contained EGFR-positive MV (data not shown.)
Figure 3A and B demonstrates the longitudinal temporal
measurements of MV production as related to the clinical history
for two patients. Figure 3A shows an example of TE/PsP that was
associated with low MV counts in patient 4. The patient had a high
MV count at the end of CRT. It dropped dramatically by day 45 and
remained low. MRIs made between 100 and 150 days were
considered equivocal, and the patient maintained a high Karnofsky
performance status score without steroids and associated low MV
values. By 170 days, MRIs were considered stable, associated with low
MV counts. Figure 3B shows an example of TP (patient 3.) At
completion of CRT, MV counts were elevated with values N1000 raw
MV counts. Subsequently, MRI studies showed progression in extent
of enhancement on fluid attenuation inversion recovery. A second
surgery was performed and confirmed recurrence. The patient was
subsequently treated with Avastin. This patient died of disease 200
days following initial surgery.
The average patient follow-up was 247 days with 9 of 11 patients
alive at the time of analysis. Six patients were alive with TP or residual
disease post second surgery (two in hospice care) and three patients
were living with TE/PsP.
Figure 4 provides the clinical outcome data as related to MV data
on 11 patients with 19 imaging sessions and 7 normal volunteers as
“box and whiskers” plots. In this small study, there was a statistically
significant difference in the MV count at or near the time of TP
compared to patients who responded to treatment (TE/PsP) (P =
.014). The MV values from the volunteers was statistically different
than the patients with TP (P = .04).
Figure 3. Examples of longitudinal collection of MV samples from two patients. The green line at ≈ 1000 represents the median value of
volunteers. The upper panel shows an example of TE/PsP characterized by lowMVcounts; thiswas sustained over time. The lower panel shows
TP as very elevated MV values (label D); this was 23 days before the radiographic diagnosis of TP. A second surgery was performed and
recurrencewas confirmed. Post-operatively and after initiation of Avastin therapy,MV counts decreased (labels F-G). The patient died of disease
200 days following initial surgical diagnosis. In both panels, the timeline shown is the same (300 days) for ease of comparison.
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were elevated at the time of simulation, they tended to decrease—
although not necessarily to normal—by the end of CRT; (b)
patients with low MV numbers at the start of CRT and did not
have TP tended to have low MV at the end of CRT; (c) TP was
associated with increased MV values greater or much greater
than 965 raw MV count, the working “cutoff” based on blood
from normal volunteers; and (d) in most patients, therapeutic
interventions (i.e., radiation, Avastin, and surgery) resulted in a
decreased MV count.Discussion
We hypothesized that the FCM-based number of Annexin V–positive
circulating MV could be used in real time as a biomarker for
differentiating TP versus TE/PsP in GB patients receiving CRT
followed by standard therapies. Our preliminary findings (Figure 4)
support that hypothesis, where following CRT, GB patients with
TP have elevated Annexin V–positive MV compared to patients with
TE/PsP (P = .014).
Controversy exists over the best methods to differentiate TP from
TE/TP. A recent systematic review of the imaging literature concluded
Figure 4. Results from 11 patients with 19 MRI images, plotted as
“box andwhiskers” plots. Each data element for this graph is based
on an MRI imaging reading and a temporally associated MV
measurement. Thus, there may be more than one data point for
each patient. The bottom and top of each box represents the first
and third quartiles, and the band inside the box is the second
quartile (the median). The “whiskers” represent the lowest datum
still within 1.5 interquartile range of the lower quartile and the
highest datum still within 1.5 interquartile range of the upper
quartile. The small circles represent outliers. The MV counts in
patients that experienced TP were statistically different from
the volunteers (P = .04). The MV counts in patients at the point
that they experienced TP were statistically higher than that from
patients with TE/PsP (P = .014).
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MRI, is the most sensitive and specific imaging modality [10]. However,
the standard response criteria for GB RANO are based on MRI imaging
plus clinical considerations (Karnofsky performance status and steroid
dependence) [11]. Since MRI changes are not specific for TP versus TE/
PsP, there is a possibility for misdiagnosis in a substantial number of
patients, and therefore, new methods of imaging patients with GB are
desirable. Positron emission tomography imaging [12], diffusion tensor
imagingMRI [13], andmagnetic resonance perfusion are being explored.
Non–imaging-based tumor biomarkers such as Ki67 [14] and MGMT
[15] have been reported to be prognostic in some studies. However, these
markers only provide a probability of a patient developingTE/PsP (vsTP)
and are not specific to a patient at a given time.Newermethods including
those based on circulating tumor cells and/or naked DNA are beginning
to approach this question [16].
Only a few studies on blood-borne MV isolated from patients with
GB have been published. One of the earliest studies was published in
2008 by Skog et al. [17]. GB patient’s tumor biopsies and serum-
derived MV were analyzed for RNA and proteins that may promote
tumor growth and provide diagnostic biomarkers. Twenty-five
patient samples were studied and seven (28%) were positive for the
EGFR vIII mutation. More recent studies of blood-borne MV have
shown that patients with GB have downregulated levels of RNA coding
for ribosomal production compared to normal controls [18]. The work
from the Belting Laboratory has demonstrated that exosomes frompatients with GB are enriched in several hypoxia-regulated proteins
known to have important roles in GB pathology [19].
The work presented herein is preliminary, but if confirmed in a
larger study, it will have substantial clinical significance. The ability to
differentiate TP from TE/PsP will allow for improved confidence in
treatment decisions and potentially improve patient survival. When
MRI studies are equivocal, the current recommendation is to re-
image patients in 1 month to determine whether the changes persist
or progress. Sometimes the changes are slow enough that multiple
months may pass before clinical and/or imaging findings are
definitive. If TE/PsP could be differentiated from TP earlier in the
disease course, patients with TP could more rapidly be offered a
change to more effective therapy. Figure 3B gives an example of TP
(patient 4); the MV count supporting TP was proposed 23 days
before MRI changes were definitive enough to change therapy.
Patients with TE/PsP could be spared more aggressive therapy.
Another application of these findings is the possibility to decrease
medical costs and patient morbidity. Many patients are taken for
surgical biopsy/resection when their MRI studies are equivocal for
TE/PsP versus TP, increasing costs and potential morbidity. If a
blood-based test could help differentiate these conditions, the number
of additional invasive therapies could be reduced. In addition, the
number of patients on clinical trials to test new therapies could be
decreased. Patients who are misdiagnosed (i.e., diagnosed as TP when
truly TE/PsP) and treated on clinical trials increases the number
of patients needed to identify a significant effect because only a
fraction of the subjects are able to respond to therapy. For example, if
only 50% of patients on a therapeutic trial have TP, the trial could
require nearly 10-fold more patients to identify efficacy [4]. In the
future, the study of MV to detect therapy response would be of
substantial importance.
In this study, we used a cutoff of 965 rawMV counts to distinguish
between “normal” and “abnormal”MV counts. There is some overlap
between groups, and therefore, there is a concern for specificity of the
assay. Co-morbidities [20–24] could confuse analysis based on a
single cutoff, and we will accrue more patients and volunteers to
determine whether we can use each patient as their own control and/
or determine a range of “normal” values. It should be noted that
several of the patients in our GB cohort had co-morbidities including
multiple sclerosis, hyperlipidemia, diabetes, and cardiac disease.
Nonetheless, our analysis of differences in MV count between TP and
TE/PsP was highly significant. It needs to be emphasized that the
proposed MV analyses are not meant to identify patients with brain
cancer, for which overlap between volunteers’ and patients’ values
would be very problematic. We propose its use in patients with
diagnosed GB who are undergoing treatment.
The possibility to “personalize” the diagnosis of TP versus TE/PsP
in patients with GB has many advantages and, based on this small
study, seems feasible. In addition to providing an early warning
system for tumor recurrence, identifying high MV values preceding
clinical and imaging changes may support the use of anti-MV
therapies. There is extensive literature supporting that MVs are
associated with aggressive tumor characteristics such as invasion and
metastasis [25,26]. Destruction of MV may be a novel therapeutic
option. Drugs are being developed for clinical use in solid cancers.
For example, Bavituximab, an antibody to PS residues [27,28],
is being used in phase III trials of solid tumors, primarily to modify
the immune system. Drugs with other mechanisms of action such
as targeting calpain are being proposed [29]. These drugs face
758 MVs as a Biomarker for TP versus TE Koch et al. Translational Oncology Vol. 7, No. 6, 2014the challenge of being specific to tumor MV without damaging
normal cells.
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